The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
|Videos|October 2, 2020
How do OAB patient education materials measure up?
Author(s)Urology Times staff
Lunan Ji, MD, discusses a recent paper published in Urology that evaluated the quality of patient education materials on YouTube related to overactive bladder.
Advertisement
In this interview, Lunan Ji, MD, discusses a paper recently published in Urology titled, “Evaluating the Quality of Overactive Bladder Patient Education Material on YouTube: A Pilot Study Using the Patient Education Materials Assessment Tool," for which he served as a study author. Ji is a urologist at Baptist Health South Florida in South Miami.
Advertisement
Related to this article
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
3
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5